Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial
The Phase II TAPISTRY trial evaluates atezolizumab in patients with high tumor mutational burden (TMB ≥13 or ≥16 mut/Mb), showing an objective response rate of approximately 20-22% across various solid tumors with a manageable safety profile.